miRNA Compositions and Methods for Treating Angiogenesis and Fibrosis
Tulane researchers have developed a novel microRNA-based therapeutic targeting miR-23 and miR-27 to treat age-related macular degeneration (AMD) and related vascular eye diseases. This innovative approach demonstrated significant fibrosis reduction in preclinical models and may offer a more durable, less invasive alternative to current anti-VEGF injection therapies.
The Problem
Age-related macular degeneration affects 12 million Americans and is the leading cause of blindness in developed countries, accounting for 8.7% of global blindness. Current anti-VEGF treatments require repeated invasive intravitreal injections that lack durability and carry complication risks. Dysfunction of microRNAs miR-23 and miR-27 has been implicated in AMD and other retinal diseases.
The Solution
This microRNA-based drug targets the VEGF pathway by modulating miR-23 and miR-27 expression. Preclinical testing in a laser-induced AMD mouse model demonstrates proof of concept, with the therapeutic significantly reducing ocular fibrosis compared to placebo. The approach may eliminate the need for repeated injections and reduce treatment-related complications.
The Opportunity
The technology addresses the $38 billion ophthalmic disease treatment market, projected to reach $65 billion by 2030 at 7.8% CAGR. Anti-VEGF agents dominate with over 32% market share, with leading AMD drugs generating $1.5+ billion annually. Beyond AMD, this microRNA platform has potential applications for treating other ocular vascular diseases, offering a differentiated therapeutic approach in a rapidly growing market segment.
